FIELD: veterinary medicine.
SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.
EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.
2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREVENTION OF BLEEDING CAUSED BY THE APPLICATION OF ANTIAGREGANTS, EXPERIMENT STAGE | 2017 |
|
RU2645630C1 |
| METHOD FOR PREVENTING BLEEDING CAUSED BY USE OF WARFARIN IN EXPERIMENT | 2016 |
|
RU2645414C1 |
| METHOD FOR PREVENTING INTRAOPERATIVE BLEEDING CAUSED BY PREOPERATIVE INTRODUCTION OF HEPARINE | 2013 |
|
RU2544805C1 |
| METHOD OF PREVENTING BLEEDING CAUSED BY USE OF STREPTOKINASE IN EXPERIMENT | 2014 |
|
RU2552339C1 |
| MEDICINAL PRODUCT WITH ANTICOAGULANT (INHIBITOR OF FACTOR IIA), ANTITHROMBOTIC, ANTI-INFLAMMATORY ACTIVITIES AND CONTAINING 5,7-DI(THIOPHEN-2-IL)-4,5-DIHYDRO-[1,2,4]TRIAZOLO[1,5-a ]PYRIMIDINE | 2022 |
|
RU2798587C1 |
| ANTICOAGULANT DRUG, WHICH IS A SYNTHETIC DIPEPTIDE Ac-Trp-Arg-Pip·HCl, A PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTICOAGULANT DRUG | 2019 |
|
RU2712194C1 |
| METHOD OF THROMBOSIS TREATMENT OR PREVENTION WITH APPLICATION OF DABIGATRAN ETEXILATE OR ITS SALT WITH IMPROVED EFFICIENCY IN COMPARISON WITH STANDARD TREATMENT WITH WARFARIN | 2009 |
|
RU2530645C2 |
| METHOD FOR PREVENTION OF CHRONIC SUBLEME COAGULOPATHY IN RATS IN EXPERIMENT | 2022 |
|
RU2788609C1 |
| METHOD FOR PREVENTING CHRONIC MOLYBDENUM COAGULOPATHY | 2020 |
|
RU2739690C1 |
| METHOD FOR PREVENTING CHRONIC LEAD COAGULOPATHY IN EXPERIMENTAL ANIMALS | 2019 |
|
RU2706386C1 |
